Research graph
References from PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; sevabertinib for lung cancer, gemcitabine intravesical system and durvalumab for bladder cancer, azacitidine for leukemia, cemiplimab for skin cancer, and ropeginterferon alfa-2b for essential thrombocythemia. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
External reference
10.1056/nejmoa2511065
10.1056/nejmoa2511065 · 2025 · External reference
10.1200/jco-25-01651
10.1200/jco-25-01651 · 2025 · External reference
10.1056/nejmoa2004444
10.1056/nejmoa2004444 · 2020 · External reference
10.1056/nejmoa1805131
10.1056/nejmoa1805131 · 2018 · External reference
10.1056/nejmoa2502449
10.1056/nejmoa2502449 · 2025 · External reference
10.1016/s0140-6736(25)01897-5
10.1016/s0140-6736(25)01897-5 · 2025 · External reference
10.1016/s2352-3026(25)00264-9
10.1016/s2352-3026(25)00264-9 · 2025 · External reference
Unresolved reference
External reference
